

Citrin Foundation CITRIN FOUNDATION IN-PERSON GLOBAL SYMPOSIUM 2023

SCIENTIFIC PROGRAM

Day 1 Program - Monday, Sept 18th 2023				Duration (mins)		
Session 1 – Overview (Co-Chairs: Barbara Yu, Yen How Tai)						
Time	Speaker	Description	Presentation	Q&A	Total	
9:00	Barbara Yu & Yen How Tai Citrin Foundation	Opening Speech	30	10	40	
9:40	John Walker (Nobel Laureate) The University of Cambridge, UK	Keynote Speech – Citrin Deficiency: the Questions and the Paths to Answers	30	10	40	
10:20	Johannes Häberle University Children's Hospital Zürich, University of Zürich, Switzerland	The linkage of biochemistry and pathophysiology of citrin deficiency to clinical presentations, current research landscape and unanswered questions	20	10	30	
10:50		Morning Break	30 30		30	
11:20	Hannele Yki-Järvinen University of Helsinki, Finland	Citrin Deficiency Associated Liver Disease (CDALD) in Adults, Pathophysiology and Potential Therapeutic Implications	20	10	30	
	Session 2 – Deve	elopments in the Basic Scientific Understanding of Citrin Deficiency (Chair: John Walker)				
11:50	Sotiria Tavoulari The University of Cambridge, UK	Development of cellular models to elucidate pathogenic mechanisms in citrin deficiency	30	10	40	
12:30	Diana Stojanovski The University of Melbourne, Australia	The molecular mechanisms of Citrin biogenesis in health and disease	20	10	30	
13:00	Lunch + Photoshoot 75			75		
14:15	Georgios Makris University Children's Hospital Zürich, University of Zürich, Switzerland	Biochemical, cellular and functional methods for studies of citrin deficiency	15	5	20	
	Session 3 – N	lovel Therapies I – Protein Replacement & Gene Therapies (Chair: Johannes Häberle)				
14:35	Laura Contreras Universidad Autónoma de Madrid, Spain	Evaluation of aralar as citrin replacement: exogenous aralar partially recovers MAS activity in citrin KO mitochondria	30	10	40	
15:15	Gerald Schwank University of Zürich, Switzerland	Correcting metabolic liver diseases by in vivo base- and prime editing	20	10	30	
15:45	Julien Baruteau Great Ormond Street Institute of Child Health, University College London, UK	Messenger RNA therapy for liver inherited metabolic diseases	15	5	20	
16:05	Poster Session		120		120	
18:05	Evening Break 85			85		
19:30	Conference Dinner					



	Day 2 Program – Tuesday, Sept 19th 2023			Duration (mins)		
		ion 4 - Novel Diagnostic Tools & Center Initiatives (Chair: Barbara Yu)		<u> </u>		
Time	Speaker	Description	Presentation	Q&A	Total	
9:00	Kimitoshi Nakamura Kumamoto University, Japan	Establishing early diagnosis and long-term follow-up for CD with management guidelines	30	10	40	
9:40	Johannes Häberle University Children's Hospital Zürich, University of Zürich, Switzerland	Quantification of the urea cycle flux and biomarker detection as novel diagnostic tools for citrin deficiency	20	10	30	
10:10	Nicola Longo University of Utah, USA	Identification of Citrin Deficiency by Newborn Screening in Utah	15	5	20	
10:30		Morning Break	30		30	
	Session 5	- Emerging Clinical Evidence on Citrin Deficiency (Chair: Robin Lachmann)				
11:00	Ituro Inoue National Institute of Genetics, Japan	Lessons from liver tissues of CTLN2 patients	20	10	30	
11:30	Masahide Yazaki Shinshu University, Japan	Therapeutic Experiences including LOLA for CTLN2 Patients	20	10	30	
12:00	Kimihiko Oishi The Jikei University School of Medicine, Japan	Clinical Biochemical Characteristics of Citrin Deficiency in Japan	20	10	30	
12:30	Shirou Matsumoto Kumamoto University, Japan	Clinical trial in single center: Treatment with L-carnitine, MCT oil and Amino acids for Citrin Deficiency	15	5	20	
12:50	7. 1	Announcement	10		10	
13:00		Lunch	60		60	
14:00	Marc Hellerstein University of California at Berkeley, USA	Metabolic Pathogenesis of CD: Applying New Stable Isotope-Mass Spectrometric Flux Measurements Combined with Innovative Tools to Manipulate Cytosolic Redox	20	10	30	
	Session 6 – Novel Therapie	es II – Development of Therapeutic Interventions for Citrin Deficiency (Chair: Edmund Kur	nji)			
14:30	Paolo Martini Moderna, Inc., USA	Messenger RNA therapy is a platform therapeutic for the treatment of Rare Genetic Disorders	20	10	30	
15:00	Joseph Baur University of Pennsylvania, USA	Modulating NAD+ Availability in Mice with Citrin Deficiency	20	10	30	
15:30	Short Break		10		10	
15:40	Yukio Nagasaki University of Tsukuba, Japan	Innovations in Amino Acid donors: Design and implementation using amphiphilic block copolymer micelles	20	10	30	
16:10	Marc Prentki Montreal Diabetes Research Center, CRCHUM, Canada	Targeting liver glycerol-3-phosphate phosphatase and the glycerol shunt for citrin deficiency	15	5	20	
16:30		Afternoon Break	30		30	



	Session 7 - Global insights on Citrin Deficiency and Other Relevant Inborn Errors of Metabolism (Chair: Nicola Longo)				
17:00	Saikat Santra Birmingham Women's and Children's NHS Foundation Trust, UK	Variation in the FTTDCD Phase of Citrin Deficiency in Two Ethnic Groups in the UK	15	5	20
17:20	Robin Lachmann University College London Hospitals NHS Foundation Trust, UK	Citrin Deficiency and other UCDs in Adults	15	5	20
17:40	Ljubica Caldovic Children's National Hospital, USA	Transcriptional regulation of citrin gene: A datamining approach	15	5	20
18:00	Alice Sowton The University of Cambridge, UK	Presentation by winner of the Poster Session	10	5	15
18:15	Nguyen Thi Mai Huong National Children's Hospital Hanoi, Vietnam	Presentation by winner of the Poster Session	10	5	15
18:30	John Walker <i>The University of Cambridge, UK</i>	Closing remarks	5		5
18:35	Evening Break 55			55	
19:30	Gala Dinner (Speeches: Barbara Yu & Yen How Tai)				



POSTER PRESENTATIONS (ALPHABETISED ACCORDING TO LAST NAME)

Name	Title	
Araceli del ARCO		
Centro de Biología Molecular Severo Ochoa CSIC-	Citrin replacement with Aralar: dissecting Citrin-Aralar interactions	
UAM, Spain		
Eri IMAGAWA	A new drug trial for citrin deficiency with triheptanoin, a medium-odd-chain heptanoic acids (C7), using a mouse model	
The Jikei University School of Medicine, Japan	A new drug that for citim dentiency with timeptanom, a medium-odd-chain neptanole acids (e7), dsing a modse model	
Bosco JOSE	Development and characterization of cellular Citrin Deficiency models	
The University of Cambridge, UK		
Jun KIDO	Selected amino acids and acylcarnitines may effectively detect newborns with citrin deficiency in the newborn screening	
Kumamoto University, Japan	Selected arillio acids and acylearnitines may effectively detect newborns with citim deficiency in the newborn screening	
Yuta KODA	Poly(amino acid)-Based Self-Assembling Polymer Drugs Enhancing the Efficacy of Chemotherapy by Continuous Release of Amino Acids	
University of Tsukuba, Japan	Tory (animo acid) based Self-Assembling Foryther brugs Enhancing the Emcacy of Chemotherapy by Continuous Release of Animo Acids	
Li Eon KUEK	From Challenges to Solutions: Advancing Pre-clinical Models in Citrin Deficiency Research	
Citrin Foundation, Singapore	Trom chanenges to solutions. Advancing Fre-clinical Models in Citim Denciency Nesearch	
NGUYĒN Thanh Phuong	Molecular relevance of citrullinemia type II and liver cancer	
National Institute of Genetics, Japan	Willectular relevance of citruminernia type if and liver caricer	
NGUYEN Thi Mai Huong	The mutation spectrum of the SLC25A13 gene in pediatric cohort in Vietnam	
National Children's Hospital Hanoi, Vietnam	The mutation spectrum of the Stc25A15 gene in pediatric conort in vietnam	
Catherine PALMER	The molecular mechanisms of Citrin biogenesis in health and disease	
The University of Melbourne, Australia	The molecular mechanisms of Citrin biogenesis in health and disease	
Alice SOWTON	Pigenergatic Profiling of Collular Models of Citrin Deficiency	
The University of Cambridge, UK	Bioenergetic Profiling of Cellular Models of Citrin Deficiency	
Toni VUKOVIC		
University Children's Hospital Zürich, University of	Citrin knock-out HepaRG cells as a model for citrin deficiency	
Zürich, Switzerland		